New molecular targets in the pathophysiology of obesity and available treatment options under investigation (Q38397535)

2 September 2017

1 reference

title

New molecular targets in the pathophysiology of obesity and available treatment options under investigation (English)

1 reference

2 September 2017

0 references

G Valsamakis

1

1 reference

2 September 2017

K Lois

series ordinal

2

1 reference

2 September 2017

S Kumar

series ordinal

3

1 reference

2 September 2017

G Mastorakos

series ordinal

4

1 reference

2 September 2017

language of work or name

1 reference

23 June 2014

1 reference

2 September 2017

1 reference

2 September 2017

volume

4

1 reference

2 September 2017

issue

4

1 reference

2 September 2017

page(s)

209-219

1 reference

Anti-obesity drugs: past, present and future

2 September 2017

cites work

1 reference

Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients

21 January 2018

1 reference

21 January 2018

1 reference

Leptin action in the forebrain regulates the hindbrain response to satiety signals.

21 January 2018

1 reference

Effects of weight loss and leptin on skeletal muscle in human subjects

21 January 2018

1 reference

Congenital leptin deficiency is associated with severe early-onset obesity in humans

21 January 2018

1 reference

Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial

21 January 2018

1 reference

Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial

21 January 2018

1 reference

Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene

21 January 2018

1 reference

Reduction of hypothalamic protein tyrosine phosphatase improves insulin and leptin resistance in diet-induced obese rats

21 January 2018

1 reference

Endoplasmic reticulum stress plays a central role in development of leptin resistance

21 January 2018

1 reference

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy

21 January 2018

1 reference

Sertraline enhances the effects of cognitive-behavioral treatment on weight reduction of obese patients

21 January 2018

1 reference

WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity

21 January 2018

1 reference

Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization

21 January 2018

1 reference

Topiramate: a review of preclinical, pharmacokinetic, and clinical data

21 January 2018

1 reference

A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity

21 January 2018

1 reference

Topiramate-Induced Acute Bilateral Angle Closure and Myopia: Pathophysiology and Treatment Controversies

21 January 2018

1 reference

Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register

21 January 2018

1 reference

Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial

21 January 2018

1 reference

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Subtypes Y1 and Y2 of the Neuropeptide Y Receptor Are Respectively Expressed in Pro-Opiomelanocortin- and Neuropeptide-Y-Containing Neurons of the Rat Hypothalamic Arcuate Nucleus

21 January 2018

1 reference

Neuronal circuits involving neuropeptide Y in hypothalamic arcuate nucleus-mediated feeding regulation

21 January 2018

1 reference

Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults

21 January 2018

1 reference

New central targets for the treatment of obesity

21 January 2018

1 reference

Approaches to the pharmacological treatment of obesity

21 January 2018

1 reference

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

21 January 2018

1 reference

The biology of incretin hormones

21 January 2018

1 reference

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study

21 January 2018

1 reference

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults

21 January 2018

1 reference

Clinical Efficacy and Safety of Once-Weekly Glucagon-Like Peptide-1 Agonists in Development for Treatment of Type 2 Diabetes Mellitus in Adults

21 January 2018

1 reference

Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes

21 January 2018

1 reference

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

21 January 2018

1 reference

Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects

21 January 2018

1 reference

Inhibition of food intake in obese subjects by peptide YY3-36

21 January 2018

1 reference

Effect of peptide YY3-36 on food intake in humans

21 January 2018

1 reference

PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.

21 January 2018

1 reference

Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults

21 January 2018

1 reference

Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice

21 January 2018

1 reference

Peripheral oxyntomodulin reduces food intake and body weight gain in rats.

21 January 2018

1 reference

Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure

21 January 2018

1 reference

Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial

21 January 2018

1 reference

Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial

21 January 2018

1 reference

DPP‐IV‐resistant, long‐acting oxyntomodulin derivatives

21 January 2018

1 reference

(D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions

21 January 2018

1 reference

Ghrelin and energy balance: focus on current controversies

21 January 2018

1 reference

Vaccination against weight gain

21 January 2018

1 reference

Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists

21 January 2018

1 reference

Inhibition of ghrelin O-acyltransferase (GOAT) by octanoylated pentapeptides.

21 January 2018

1 reference

Roles of pancreatic polypeptide in regulation of food intake

21 January 2018

1 reference

Pancreatic polypeptide reduces appetite and food intake in humans

21 January 2018

1 reference

Regulation of appetite to treat obesity

21 January 2018

1 reference

Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression

21 January 2018

1 reference

Amylin decreases meal size in rats

21 January 2018

1 reference

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients

21 January 2018

1 reference

Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes

21 January 2018

1 reference

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

21 January 2018

1 reference

Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies

21 January 2018

1 reference

Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms

21 January 2018

1 reference

Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity

21 January 2018

1 reference

Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial

21 January 2018

1 reference

Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone.

21 January 2018

1 reference

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects

21 January 2018

1 reference

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/COB.12064

1 reference

2 September 2017

1 reference